Tag: ado-trastuzumab emtansine
Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...
Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...
Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...
Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates
A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...
Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...
The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...
Synaffix’s New High Potency Lab now Fully Operational to Support Growing...
Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...
Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer...
Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in December...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial
Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...
Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...
Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...
